Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Australian Gov’t. Grants Provisional Approval To J&J’s COVID-19 Vaccine

-Reuters

byBenzinga Newsdesk

June 25, 2021

1 minute read

-Reuters

BEST Q3 EPS $(0.59) Misses $(0.07) Estimate, Sales $285.30M Miss $378.61M Estimate

By Bill Haddad

Today, 5:27 AM

BEST (NYSE:BEST) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.07) by 742.86 percent. This is a 56.3 percent increase over losses of $(1.35) per share from the same

BEST

JP Morgan Assumes BeiGene at Overweight, Announces Price Target of $296

By Benzinga Newsdesk

Today, 5:27 AM

JP Morgan analyst Xiling Chen assumes BeiGene (NASDAQ:BGNE) with a Overweight rating and announces Price Target of $296.

BGNE

FDA Approves First Branded Ocular Anesthetic In Almost 14 Years

By Vandana Singh

Today, 5:27 AM

The FDA approved Harrow Health Inc (NASDAQ:HROW) and Sintetica S.A’s Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Iheezo is a…

HROW

J&J’s Xarelto Tops Aspirin With Fewer Blood Clots In Pediatric Patients

By Vandana Singh

Today, 5:27 AM

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE:JNJ), announced new data from the Phase 3 UNIVERSE study comparing Xarelto (rivaroxaban). The…

JNJ

Australian Gov’t. Grants Provisional Approval To J&J’s COVID-19 Vaccine

Related Posts

BEST Q3 EPS $(0.59) Misses $(0.07) Estimate, Sales $285.30M Miss $378.61M Estimate

JP Morgan Assumes BeiGene at Overweight, Announces Price Target of $296

FDA Approves First Branded Ocular Anesthetic In Almost 14 Years

J&J’s Xarelto Tops Aspirin With Fewer Blood Clots In Pediatric Patients